Radium-223

Origin and preparation

Although radium-223 is naturally formed in trace amounts by the decay of uranium-235, it is generally made artificially, by exposing natural radium-226 to neutrons to produce radium-227, which decays with a 42-minute half-life to actinium-227. Actinium-227 (half-life 21.8 years) in turn decays via thorium-227 (half-life 18.7 days) to radium-223. This decay path makes it convenient to prepare radium-223 by "milking" it from an actinium-227 containing generator or "cow", similar to the moly cows widely used to prepare the medically important isotope technetium-99m.

223Ra itself decays to 219Rn (half-life 3.96 s), a short-lived gaseous radon isotope, with total energy 5.979 MeV.

Medical uses

| Drugs.com =

| elimination_half-life =

The pharmaceutical product and medical use of radium-223 against skeletal metastases was invented by Roy H. Larsen, Gjermund Henriksen and Øyvind S. Bruland and has been developed by the former Norwegian company Algeta ASA, in a partnership with Bayer, under the trade name Xofigo (formerly Alpharadin), and is distributed as a solution containing radium-223 chloride (1100 kBq/ml), sodium chloride, and other ingredients for intravenous injection. Algeta ASA was later acquired by Bayer who is the sole owner of Xofigo.

Mechanism of action

The use of radium-223 to treat metastatic bone cancer relies on the ability of alpha radiation from radium-223 and its short-lived decay products to kill cancer cells. Radium is preferentially absorbed by bone by virtue of its chemical similarity to calcium, with most radium-223 that is not taken up by the bone being cleared, primarily via the gut, and excreted. Although radium-223 and its decay products also emit beta and gamma radiation, over 95% of the decay energy is in the form of alpha radiation. Alpha radiation has a very short range in tissues compared to beta or gamma radiation: around 2–10 cells. This reduces damage to surrounding healthy tissues, producing an even more localized effect than the beta-emitter strontium-89, also used to treat bone cancer. Taking account of its preferential uptake by bone and the alpha particles' short range, radium-223 is estimated to give targeted osteogenic cells a radiation dose at least eight times higher than other non-targeted tissues.

Clinical trials and FDA and EMA approval

The phase II study of radium-223 in castration-resistant prostate cancer (CRPC) patients with bone metastases showed minimum myelotoxicity and good tolerance for the treatment.

223Ra successfully met the primary endpoint of overall survival in the phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer patients) study for bone metastases resulting from CRPC in 922 patients.

The ALSYMPCA study was stopped early after a pre-planned efficacy interim analysis, following a recommendation from an Independent Data Monitoring Committee, on the basis of achieving a statistically significant improvement in overall survival (two-sided p-value = 0.0022, HR = 0.699, the median overall survival was 14.0 months for 223Ra and 11.2 months for placebo). Earlier phase II of the trial showed a median increased survival of 18.9 weeks (around 4.4 months). The lower figure of 2.8 months increased survival in interim phase III results is a probable result of stopping the trial; median survival time for patients still alive could not be calculated. A 2014 update indicates a median increased survival of 3.6 months.

In May 2013, 223Ra received marketing approval from the US Food and Drug Administration (FDA) as a treatment for CRPC with bone metastases in people with symptomatic bone metastases and without known visceral disease. 223Ra received priority review as a treatment for an unmet medical need, based on its ability to extend overall survival as shown its Phase III trial.

This study also led to approval in the European Union in November 2013, The European Medicines Agency subsequently recommended restricting its use to patients who have had two previous treatments for metastatic prostate cancer or who cannot receive other treatments. The medicine must also not be used with abiraterone acetate, prednisone or prednisolone and its use is not recommended in patients with a low number of osteoblastic bone metastases.

223Ra also showed promising preliminary results in a phase IIa trial enrolling 23 women with bone metastases resulting from breast cancer that no longer responds to endocrine therapy. 223Ra treatment reduced the levels of bone alkaline phosphatase (bALP) and urine N-telopeptide (uNTX), key markers of bone turnover associated with bone metastases in breast cancer, diminished bone pain slightly though consistently, and was well tolerated. Another single-arm, open-label Phase II trial reported possible efficacy of 223Ra combined with endocrine therapy in hormone-receptor-positive, bone-dominant breast cancer metastasis.

Side effects

The most common side effects reported during clinical trials in men receiving 223Ra were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing were anemia, lymphocytopenia, leukopenia, thrombocytopenia and neutropenia.

Other radium-223-based compounds

Although radium does not easily form stable molecular complexes, data has been presented on methods to increase and customize its specificity for particular cancers by linking it to monoclonal antibodies, by enclosing the 223Ra in liposomes bearing the antibodies on their surface.

References

References

1. {{AME2020 II
2. {{NUBASE2020
3. {{NNDC
4. (1905). "A new radio-active product from actinium". Nature.
5. (1905). "V. Actinium and its successive products". The London, Edinburgh, and Dublin Philosophical Magazine and Journal of Science.
6. (1906). "A new product of actinium". Nature.
7. (1971). "The discovery of actinium". Isis.
8. (2013). "Discovery of actinium, thorium, protactinium, and uranium isotopes". Atomic Data and Nuclear Data Tables.
9. (2017). "Medical-Surgical Nursing: Assessment and Management of Clinical Problems". Elsevier.
10. (July 2018). "Targeted alpha therapy using Radium-223: From physics to biological effects". Cancer Treatment Reviews.
11. Bruland O.S., Larsen R.H. (2003). Radium revisited. In: Bruland O.S., Flgstad T., editors. Targeted cancer therapies: An odyssey. University Library of Tromso, Ravnetrykk No. 29. {{ISBN. 82-91378-32-0, pp. 195–202. [http://www.bruland.info/PDF/195-202.pdf] {{Webarchive. link. (21 April 2016)
12. (21 June 2022). "Prescription medicines: registration of new chemical entities in Australia, 2014".
13. (10 December 2019). "Xofigo- radium ra 223 dichloride injection".
14. (13 November 2013). "Xofigo EPAR".
15. "Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning" US 6635234
16. (11 October 2018). "Xofigo Summary of Product Characteristics". Bayer.
17. (June 2005). "First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases". Clinical Cancer Research.
18. (October 2006). "High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?". Clinical Cancer Research.
19. (February 2003). "Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice". Journal of Nuclear Medicine.
20. (July 2007). "Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study". The Lancet. Oncology.
21. [http://prostatecancerinfolink.net/2011/09/26/full-data-report-from-the-alsympca-trial-of-radium-223-presented/ Full data report from the ALSYMPCA trial of radium-223 presented]
22. (18 July 2013). "Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer". New England Journal of Medicine.
23. "FDA approves new drug for advanced prostate cancer". U.S. [[Food and Drug Administration]] (FDA).
24. (21 June 2013). "Drug Approval Package: Xofigo (radium Ra 223 dichloride) Injection NDA #203971".
25. (17 September 2018). "Xofigo".
26. (28 September 2018). "EMA restricts use of prostate cancer medicine Xofigo".
27. (June 2014). "A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease". Breast Cancer Research and Treatment.
28. (February 2020). "Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer". Cancer Medicine.
29. (May 2002). "Evaluation of potential chelating agents for radium". Applied Radiation and Isotopes.
30. (May 2004). "Sterically stabilized liposomes as a carrier for alpha-emitting radium and actinium radionuclides". Nuclear Medicine and Biology.